LMR Partners’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

LMR Partners’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,440,169	Closed	-$622K	–	1255
2023 Q1	$622K	Hold	2,440,169	–	–	0.01%	676
2022 Q4	$2.88M	Hold	2,440,169	–	–	0.05%	410
2022 Q3	$4.98M	Buy	2,440,169 +500,000	+26%	+$73.3K	0.09%	276
2022 Q2	$2.99M	Buy	1,940,169 +619,334	+47%	+$306K	0.05%	412
2022 Q1	$6.67M	Buy	1,320,835 +1,258,733	+2,027%	+$881K	0.08%	264
2021 Q4	$385K	Hold	62,102	–	–	﹤0.01%	972
2021 Q3	$617K	Buy	62,102 +12,102	+24%	+$12.6K	0.01%	747
2021 Q2	$74K	Buy	+50,000	New	+$43.6K	﹤0.01%	925

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

LMR Partners's PEARW Position: Q2 2023 in Review

LMR Partners sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 2,440,169 shares — an estimated $622K sold.

LMR Partners first reported a position in PEARW in Q2 2021 and held it in 8 quarters. The position peaked at $6.67M in Q1 2022. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

LMR Partners reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 2,440,169 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $622K.
LMR Partners first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 8 quarters.
LMR Partners's Pear Therapeutics, Inc. Warrant position peaked at $6.67M in Q1 2022.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.